Heron Therapeutics Inc vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $74.04M), while Royalty Pharma plc Class A Ordinary Shares trades at $56.2 (market cap $25.27B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 341.3× Heron Therapeutics Inc's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Royalty Pharma plc Class A Ordinary Shares for 0 Days on average.
| HRTX | RPRX | |
|---|---|---|
Market Cap | $74.04M | $25.27B |
Volume | 3,668,095 | 3,671,183 |
Sector | Health | Health |
52-Week High | $1.49 | $63.96 |
52-Week Low | $0.27 | $35.44 |
Typical Hold Time | 35 Days | 0 Days |
Enterprise Value | $180.78M | $32.50B |
Dividend Yield | — | 1.66% |
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →